QuellTX Logo
t: 0207 096 9012
Quell Logo ×

Restoring the Balance With Regulatory T cell Therapies

Harnessing the suppressive capacity of Tregs to address immune dysfunction utilising modular engineered Tregs Addressing a range of autoimmune and inflammatory diseases as well as preventing rejection in organ transplantation

Welcome to Quell

Quell Therapeutics is a London, UK based, private biopharmaceutical company. Our vision is to be the leading engineered cell therapy company, bringing transformational and valued therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

About Us

Quell was founded in partnership with six world leading experts in the field of immunology from King’s College London, University College London and Hannover Medical School. The Founders have made a significant contribution in the field of Immunology in understanding how to harness the suppressive capacity of Tregs in order to address immune dysfunction by utilising engineered Tregs.

More Info

The Science

Learn more about how we are developing transformational therapies using modular engineered Treg cell therapies for the treatment of a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.

More Info

The Pipeline

We are developing therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Learn more about our pipeline of products in development.

More Info

Work With Us

Quell is a culture-led organisation which LIVES its values and we respect the diverse qualities our employees bring. Learn more about working with us.

More Info

Latest News

08/04/20

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

Collaboration will accelerate Quell’s pipeline expansion into autoimmune and inflammatory diseases London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a…...

Read More
24/02/20

T regs are back – promising to do for autoimmunity what CAR Ts have done in cancer

The following article was published in BioCentury Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new…...

Read More
23/09/19

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private…...

Read More

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.

Quell Introduction

Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.